Abstract
N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methyl-3-[(4-methylphenyl)sulfonyl]propanamide (bicalutamide) is an oral medication that is used for treating cancer of the prostate. It belongs to a class of drugs called anti-androgens. Quantum chemical studies of bicalutamide were based on Arguslab software. The steric energy was evaluated in terms of potential energy as a sum of energies associated with bonded interactions (bond length, bond angle and dihedral angle) as well as non-bonded interactions (van der Waals and electrostatic). Surfaces were created to visualize excited state properties such as highest occupied molecular orbital's, lowest unoccupied molecular orbital's and electrostatic potential (ESP) mapped density. The steric energy for bicalutamide was calculated to be 0.963933 a.u. (604.877867 kcal/mol). The most energetically favourable conformation of bicalutamide was found to have a heat of formation of 7696.375900 kcal/mol. The self-consistent field (SCF) energy was calculated by geometry convergence function using RHF/PM3 method in ArgusLab software. The most feasible position for bicalutamide to block androgen receptors on the cells of tissues was found to be-189.888176 au (−119156.737100 Kcal/mole).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Research Journal of Pharmacognosy and Phytochemistry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
